Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease
Aim. To compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn’s disease (CD). Methods. In a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn’s disease activity i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/6595048 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548472377573376 |
|---|---|
| author | Youyou Luo Jindan Yu Jingan Lou Youhong Fang Jie Chen |
| author_facet | Youyou Luo Jindan Yu Jingan Lou Youhong Fang Jie Chen |
| author_sort | Youyou Luo |
| collection | DOAJ |
| description | Aim. To compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn’s disease (CD). Methods. In a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn’s disease activity index (PCDAI), growth improvement, endoscopic mucosal healing, and adverse effects. Data were measured at baseline and after 8 weeks of therapy. Results. We enrolled 26 children with CD; of whom, 13 were treated with infliximab, 13 with EEN. Clinical response (PCDAI) reduction ≥ 15 or final PCDAI ≤ 10 was achieved by 83.3% in the EEN group and 90.9% in the IFX group. Body mass index for age (BMIFA) z-scores were significantly increased in both groups (P<0.05). No significant differences were observed in PCDAI, height for age (HFA), or BMI recovery between two groups. Adverse effects were detected in 30.7% on infliximab and 0% on EEN. Mucosal healing was achieved in 71.4% cases in the EEN group versus 85.7% in the IFX group. Conclusion. EEN provided similar improvements as IFX in clinical symptoms, mucosal healing, and BMI. EEN therapy has less adverse effects when compared with IFX. This trial is registered with the Clinical Registration Number: ChiCTR-OON-17010834. |
| format | Article |
| id | doaj-art-874ac8f1dc3646ae993ddbb35271c073 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-874ac8f1dc3646ae993ddbb35271c0732025-02-03T06:14:04ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/65950486595048Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s DiseaseYouyou Luo0Jindan Yu1Jingan Lou2Youhong Fang3Jie Chen4Department of Gastroenterology, The Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, ChinaDepartment of Gastroenterology, The Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, ChinaDepartment of Gastroenterology, The Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, ChinaDepartment of Gastroenterology, The Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, ChinaDepartment of Gastroenterology, The Children’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310051, ChinaAim. To compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn’s disease (CD). Methods. In a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn’s disease activity index (PCDAI), growth improvement, endoscopic mucosal healing, and adverse effects. Data were measured at baseline and after 8 weeks of therapy. Results. We enrolled 26 children with CD; of whom, 13 were treated with infliximab, 13 with EEN. Clinical response (PCDAI) reduction ≥ 15 or final PCDAI ≤ 10 was achieved by 83.3% in the EEN group and 90.9% in the IFX group. Body mass index for age (BMIFA) z-scores were significantly increased in both groups (P<0.05). No significant differences were observed in PCDAI, height for age (HFA), or BMI recovery between two groups. Adverse effects were detected in 30.7% on infliximab and 0% on EEN. Mucosal healing was achieved in 71.4% cases in the EEN group versus 85.7% in the IFX group. Conclusion. EEN provided similar improvements as IFX in clinical symptoms, mucosal healing, and BMI. EEN therapy has less adverse effects when compared with IFX. This trial is registered with the Clinical Registration Number: ChiCTR-OON-17010834.http://dx.doi.org/10.1155/2017/6595048 |
| spellingShingle | Youyou Luo Jindan Yu Jingan Lou Youhong Fang Jie Chen Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease Gastroenterology Research and Practice |
| title | Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease |
| title_full | Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease |
| title_fullStr | Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease |
| title_full_unstemmed | Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease |
| title_short | Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease |
| title_sort | exclusive enteral nutrition versus infliximab in inducing therapy of pediatric crohn s disease |
| url | http://dx.doi.org/10.1155/2017/6595048 |
| work_keys_str_mv | AT youyouluo exclusiveenteralnutritionversusinfliximabininducingtherapyofpediatriccrohnsdisease AT jindanyu exclusiveenteralnutritionversusinfliximabininducingtherapyofpediatriccrohnsdisease AT jinganlou exclusiveenteralnutritionversusinfliximabininducingtherapyofpediatriccrohnsdisease AT youhongfang exclusiveenteralnutritionversusinfliximabininducingtherapyofpediatriccrohnsdisease AT jiechen exclusiveenteralnutritionversusinfliximabininducingtherapyofpediatriccrohnsdisease |